RT期刊文章SR电子T1额颞叶障碍的发生率和趋势在奥姆斯特德县:基于人口的研究(1995 - 2010)。乔(p2.1 - 001)摩首页根富林明神经病学神经病学FD Lippincott Williams &威尔金斯SP p2.1补充92 - 001签证官是15 A1又是Turcano A1科尔刺伤A1米歇尔Mielke A1亚历山德拉Wennberg A1基思·约瑟夫A1 j . Ahlskog A1布拉德利Boeve A1 David Knopman A1罗纳德·彼得森A1 Rodolfo Savica年2019 UL //www.ez-admanager.com/content/92/15_supplement/p2.1 - 001. -文摘AB目的:探讨额颞叶痴呆疾病的发病率(ftd)以人群为基础的队列。背景:ftd异构表型综合症,表现为行为和语言障碍通常与额叶或颞叶退化。设计/方法:使用records-linkage系统的罗彻斯特流行病学项目中,我们发现所有患者筛查诊断代码痴呆奥姆斯特德县MN从1995年到2010年。我们使用自然语言处理软件确认ftd诊断的存在。行为神经学家证实了临床诊断和确定的临床表型。结果:我们发现35 ftd例:22(62.9%)是男性。平均诊断年龄是70岁(范围:48 - 94)。平均随访时间为3年(范围:1 12月年)。17/35(48.6%)的行为FTD变体;1有一个混合的临床诊断(行为变异+语义变体FTD);1有流利的原发性进行性失语(PPA); 1 non-fluent PPA; 1 PPA NOS; 1 had FTD with motor neuron disease; and 13/35 (37.1%) were unspecified. 10/35 (28.6%) reported depression within 5 years preceding the clinical diagnosis. 13/35 (37.1%) patients had at least one MRI before their diagnosis (range: 3 days–6 years); all presented with cortical atrophy consistent with the clinical diagnosis. 6/35 (17.1%) patients underwent PET or SPECT examination before the clinical diagnosis (range: 1 month–19 months), all showing hypometabolism of the frontal, temporal and/or parietal lobes. At autopsy, clinical diagnosis was confirmed in 6/11 (54.5%) cases. Overall FTDs incidence was 4.3/100,000 per year (95% CI 2.9, 5.7, P<0.001). Incidence was higher in men (6.3/100,000, 95% CI 3.6, 9.0, P<0.001) than women (2.9/100,000; 95% CI 1.3, 4.5, P<0.001). Incidence trended upwards over time (B= 0.83, 95% CI 0.54, 1.11, P<0.001).Conclusions: We observed an increased incidence of FTDs over time. This may reflect a better recognition by clinicians, and improvement of clinical criteria and diagnostic tools.Disclosure: Dr. Turcano has nothing to disclose. Dr. Stang has nothing to disclose. Dr. Mielke has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Lysosomal Therapeutics, Inc. Dr. Mielke has received research support from Biogen, Roche, and Lundbeck. Dr. Wennberg has nothing to disclose. Dr. Josephs has nothing to disclose. Dr. Ahlskog has nothing to disclose. Dr. Boeve has received research support from Biogen. Dr. Knopman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Washington University for the DIAN study. Dr. Knopman has received research support from Biogen Pharmaceuticals and Lilly Pharmaceuticals. Dr. Petersen has nothing to disclose. Dr. Savica has nothing to disclose.